streptococcus pneumonia

Oritavancin diphosphate (LY333328 diphosphate) is a novel semisynthetic glycopeptide antibiotic developed for treating serious Gram-positive bacterial infections.

Tebipenem Pivoxil (Orapenem) , an orally activity carbapenem antibiotic, is utilized in treating otolaryngologic and respiratory infections.

Ceftaroline fosamil hydrate acetate is a powerful cephalosporin antibiotic that exhibits broad-spectrum efficacy against both Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative bacteria. It possesses anti-infective properties suitable for studying complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) [1] [2] [3].

Grepafloxacin (OPC-17116) is a fluoroquinolone antibiotic that is administered orally. It possesses strong efficacy against community-acquired respiratory pathogens, notably Streptococcus pneumonia. Grepafloxacin exhibits excellent tissue penetration and demonstrates a promising pharmacodynamic profile.

Gemifloxacin mesylate (Gemifloxacin mesylate) inhibits activities of DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and eventually bacterial growth. Gemifloxacin Mesylate is the mesylate salt form of gemifloxacin, a synthetic broad-spectrum fluoroquinolone with antibacterial activity. This fluoroquinolone exerts an enhanced spectrum of activity against gram-positive bacteria such as Streptococcus pneumonia and Staphylococcus aureus, in addition to its activity against gram-negative bacteria.

Omadacycline, also known as PTK 0796 and Amadacyclin, is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. Omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). The primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. The binding site for omadacycline is similar to that for tetracycline.

Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.